Repaglinide Tablets 2 mg (Repaglinide)

Adult dose

1. Monotherapy The recommended initial dose is 0.5 mg of repaglinide per dose, and the dose is determined by titration at intervals of 1 or 2 weeks. Patients taking another oral hypoglycemic agent may also switch directly to this medicine; the recommended initial dose in this case is 1 mg per dose. The recommended maximum dose is 4 mg per dose. Administer before meals 2, 3, or 4 times daily, according to the patient's meal pattern. The total daily dose must not exceed 16 mg. Use particular caution when administering and titrating the dose in debilitated or malnourished patients. Although most of this medicine is excreted via the bile, caution should also be exercised in patients with renal impairment. 2. Combination therapy If blood glucose is not adequately controlled with monotherapy, this medicine may be used in combination with metformin or a thiazolidinedione. The initial dose and dose adjustment are the same as for monotherapy. Adjust the dose of each medicine very carefully to the minimum amount required to achieve the desired pharmacological effect. Inadequate adjustment may increase the occurrence of hypoglycemic symptoms. Appropriate monitoring of fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) is necessary to prevent overdose or an increased likelihood of failure of the second agent.

This medication is an agent that lowers blood sugar levels and works by stimulating insulin secretion to aid in blood sugar control. However, it can cause hypoglycemia, which is a condition where blood sugar levels become too low, so caution is required. Particularly, the risk of hypoglycemia may increase when used in conjunction with other blood sugar-lowering agents or metformin. If blood sugar is not properly controlled even with combination therapy, it may be necessary to switch to insulin treatment. Stressful situations such as infections, surgery, or trauma can also increase the likelihood of hypoglycemia. This medication should not be used in certain patients. For example, those with allergies to this medication or its components, patients with insulin-dependent diabetes, patients with diabetic ketoacidosis, pregnant or nursing women, children under 18 years of age, and patients with severe liver dysfunction. Additionally, it is prohibited to use this medication in combination with gemfibrozil. This medication is also not suitable for patients with severe infections or pre-and post-surgical conditions. Patients with impaired liver or kidney function, those taking certain medications, patients with cardiovascular disease, patients with poor nutritional status, and the elderly should use this medication cautiously. It is primarily metabolized in the liver, so in cases of liver or kidney dysfunction, blood concentration may increase, leading to a higher risk of hypoglycemia. While taking this medication, side effects such as hypoglycemia, visual disturbances, gastrointestinal disorders (abdominal pain, diarrhea, nausea, vomiting, constipation, indigestion), increased liver enzymes, erythema, itching, rashes, urticaria (in mild cases), upper respiratory infections, sinusitis, rhinitis, bronchitis, arthralgia, low back pain, headache, paresthesia, chest pain (in mild cases), urinary tract infections, dental disorders, alopecia, hemolytic anemia, pancreatitis, and skin and mucous membrane syndrome (Stevens-Johnson syndrome, rarely) may occur. Anemia and chest pain have also been reported. If you are pregnant or nursing, this medication should not be used, and its safety and efficacy in children under 18 have not been established. The elderly should also be careful as blood sugar fluctuations can be significant due to decreased physical function, necessitating regular blood sugar monitoring. Overdosage may result in hypoglycemia symptoms such as dizziness, sweating, tremors, and headache. In severe cases, consciousness may be impaired or coma may occur, requiring immediate appropriate treatment. This medication should be kept out of the reach of children and stored in its original container sealed properly.

• Hypoglycemia
• visual impairment
• abdominal pain
• diarrhea
• nausea
• vomiting
• constipation
• increased liver enzymes
• erythema
• itching

This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, to ensure safety, it is recommended to place it in a cool and dry place between 15 to 25 degrees Celsius. This helps maintain the medication's effectiveness and safety.

Appearance

Convex red round tablets

Package unit

100 tablets/bottle, 30 tablets/bottle